Advertisement


S.P. Somashekhar, MBBS, MCh(Onco), on Watson for Oncology: A Validation Study for Breast Cancer

2016 San Antonio Breast Cancer Symposium

Advertisement

S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a multidisciplinary tumor board (Abstract S6-07).



Related Videos

Cost of Care
Global Cancer Care
Breast Cancer

Peter Bach, MD, on The Global Cost of Cancer Care

Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).

Breast Cancer

Diana M. Eccles, MD, on Young Breast Cancer Patients: Results From the POSH Study

Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).

Breast Cancer

Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective

Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.

Breast Cancer

Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor–based treatment (Abstract S4-07).

Advertisement

Advertisement




Advertisement